Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

Inclusion Criteria: * 1\. Tanner stage I (prepubertal) at informed consent: males aged 3 to \<11 years ; females aged 3 to \<10 years ; * 2\. At screening, height \< -2 standard deviations (SD) for age and sex (height reference per Appendix 1); * 3\. Peak GH ≥10.0 ng/mL in any growth hormone (GH) stimulation test; * 4\. Bone age minus chronological age ≤ 1 year. Exclusion Criteria: * 1.Closed epiphyses (skeletally mature)； * 2.Severe allergic diathesis, or known hypersensitivity to growth hormone or any of its excipients； * 3.History of malignancy or current active malignancy； * 4.Systemic chronic diseases, including but not limited to moderate-to-severe anemia, hypothyroidism, chronic kidney disease, cardiovascular disease (e.g., dilated cardiomyopathy), psychiatric disorders, or congenital anomalies that require clinical intervention per the investigator's judgment. * 5.Patients with a prior diagnosis of intracranial hypertension; * 6.Patients with congenital skeletal dysplasia, or scoliosis ≥15° (or moderate or greater), limping (gait disturbance), and patients with a prior diagnosis of slipped capital femoral epiphysis ; * 7.Other types of growth and developmental disorders, including confirmed or highly suspected growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Turner syndrome, small for gestational age (SGA), short stature due to SHOX gene defects, and short stature of other identified causes; * 8\. Patients with a confirmed diagnosis of diabetes mellitus, or fasting blood glucose ≥6.1 mmol/L on two consecutive measurements.